Robert W. Baird Raises Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target to $162.00

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its target price raised by Robert W. Baird from $154.00 to $162.00 in a research report released on Monday,Benzinga reports. They currently have an outperform rating on the specialty pharmaceutical company’s stock.

Several other analysts have also weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, August 1st. Piper Sandler dropped their price target on Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating on the stock in a research report on Thursday, August 1st. JPMorgan Chase & Co. lifted their price objective on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an “overweight” rating in a report on Monday, August 19th. StockNews.com raised shares of Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 1st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $140.00 price target on shares of Jazz Pharmaceuticals in a report on Monday, September 9th. Three analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $175.33.

Jazz Pharmaceuticals Stock Up 4.9 %

JAZZ stock opened at $125.10 on Monday. The company has a market capitalization of $7.56 billion, a P/E ratio of 17.62, a PEG ratio of 0.98 and a beta of 0.57. The firm has a 50 day simple moving average of $112.92 and a 200-day simple moving average of $110.52. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals has a twelve month low of $99.06 and a twelve month high of $134.17.

Insiders Place Their Bets

In other news, EVP Neena M. Patil sold 3,700 shares of Jazz Pharmaceuticals stock in a transaction on Friday, November 8th. The stock was sold at an average price of $123.41, for a total transaction of $456,617.00. Following the transaction, the executive vice president now directly owns 33,048 shares in the company, valued at approximately $4,078,453.68. This trade represents a 10.07 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Mary Elizabeth Henderson sold 1,410 shares of the company’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $108.30, for a total value of $152,703.00. Following the completion of the sale, the senior vice president now owns 14,531 shares of the company’s stock, valued at approximately $1,573,707.30. This trade represents a 8.85 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 6,110 shares of company stock worth $720,160. 4.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its holdings in shares of Jazz Pharmaceuticals by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 6,448,689 shares of the specialty pharmaceutical company’s stock worth $776,551,000 after purchasing an additional 84,941 shares in the last quarter. LSV Asset Management increased its holdings in shares of Jazz Pharmaceuticals by 4.2% in the second quarter. LSV Asset Management now owns 2,480,563 shares of the specialty pharmaceutical company’s stock valued at $264,750,000 after buying an additional 99,705 shares in the last quarter. Pacer Advisors Inc. boosted its stake in shares of Jazz Pharmaceuticals by 15.3% during the 3rd quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock worth $233,892,000 after acquiring an additional 278,465 shares in the last quarter. Capital World Investors acquired a new position in shares of Jazz Pharmaceuticals in the 1st quarter worth $171,943,000. Finally, Baupost Group LLC MA grew its holdings in shares of Jazz Pharmaceuticals by 52.8% in the 2nd quarter. Baupost Group LLC MA now owns 1,274,248 shares of the specialty pharmaceutical company’s stock worth $136,000,000 after acquiring an additional 440,552 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.